^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MB-CART20.1
i
Other names: MB-CART20.1, MB CART20.1, anti-CD20 CAR T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Miltenyi Biotec
Drug class:
CD20-targeted CAR-T immunotherapy
Related drugs:
17d
MB-CART20.1 Lymphoma (clinicaltrials.gov)
P1/2, N=19, Active, not recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Nov 2022 --> Sep 2024 | Trial primary completion date: Feb 2022 --> Sep 2024
Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
MB-CART20.1
over1year
A Phase I Dose Finding Trial of MB-CART20.1 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (ASH 2022)
Patients underwent lymphodepletion with fludarabine (30 mg/m2) and cyclophosphamide (300 mg/m2), each from day -5 to day -3...One CRS case was managed with tocilizumab...In total 3 patients achieved a CR and remained in remission for at least one year. The two patients treated at the higher DL, achieved a CR indicating a dose-response correlation.
Clinical • P1 data
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • MB-CART20.1
over2years
MB-CART20.1 Melanoma (clinicaltrials.gov)
P1, N=15, Recruiting, Miltenyi Biomedicine GmbH | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jul 2022
Clinical • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
MB-CART20.1
over2years
MB-CART20.1 Lymphoma (clinicaltrials.gov)
P1/2, N=19, Active, not recruiting, Miltenyi Biomedicine GmbH | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
CD20 (Membrane Spanning 4-Domains A1)
|
MB-CART20.1
Share via
